RT Journal Article
T1 Synthetic nanocarriers for the delivery of polynucleotides to the eye
A1 Mendes Saraiva, Sofia
A1 Castro López, Vanessa
A1 Pañeda Vázquez-Prada, Covadonga
A1 Alonso Fernández, María José
K1 Polynucleotides
K1 Nanocarriers
K1 Ocular polynucleotide delivery
K1 Anterior segment
K1 Posterior segment
K1 Eye
AB This review is a comprehensive analysis of the progress made so far on the delivery of polynucleotide-based therapeutics to the eye, using synthetic nanocarriers. Attention has been addressed to the capacity of different nanocarriers for the specific delivery of polynucleotides to both, the anterior and posterior segments of the eye, with emphasis on their ability to (i) improve the transport of polynucleotides across the different eye barriers; (ii) promote their intracellular penetration into the target cells; (iii) protect them against degradation and, (iv) deliver them in a long-term fashion way. Overall, the conclusion is that despite the advantages that nanotechnology may offer to the area of ocular polynucleotide-based therapies (especially AS-ODN and siRNA delivery), the knowledge disclosed so far is still limited. This fact underlines the necessity of more fundamental and product-oriented research for making the way of the said nanotherapies towards clinical translation
PB Elsevier
SN 0928-0987
YR 2017
FD 2017-05-30
LK http://hdl.handle.net/10347/18359
UL http://hdl.handle.net/10347/18359
LA eng
NO Saraiva, S., Castro-López, V., Pañeda, C., & Alonso, M. (2017). Synthetic nanocarriers for the delivery of polynucleotides to the eye. European Journal Of Pharmaceutical Sciences, 103, 5-18. doi: 10.1016/j.ejps.2017.03.001
NO This is the accepted manuscript of the following article: Saraiva, S., Castro-López, V., Pañeda, C., & Alonso, M. (2017). Synthetic nanocarriers for the delivery of polynucleotides to the eye. European Journal Of Pharmaceutical Sciences, 103, 5-18. doi: 10.1016/j.ejps.2017.03.001
NO This work was supported by the European Union's Horizon 2020 - Research and Innovation Framework Programme under the Marie Sklodowska-Curie Grant agreement No. 642028 (NABBA) and by the Spanish Ministry of Economy and Competitiveness (MINECO) under Grant agreement No. RTC-2014-2375-1 (SURFeye)
DS Minerva
RD 3 may 2026